Liquid biopsies are blood tests with a growing potential in diagnostics for cancer and prenatal screening. Pre-analytical challenges, such as the need for skilled workforce and strict logistic requirements for sample transportation are limiting the global full exploitation of the method. To address these challenges, we developed a method for immediate and automated sample processing that provides a sample with higher reliability, less human labor, less transport requirements and measured quality.
BiopSense innovation is a fully automated disposable cartridge, where the blood is processed and cfDNA is isolated in an automatic system.
In this EIC Transition project spanning three years (2022 – 2025) our objective is to validate the technology and to integrate all the features of the innovation into a disposable cartridge, which will be ready for marketing, licensing and IVD validation. The design will be done in close collaboration with the customer sectors and the regulatory agencies.
The history of the innovation lies in the background knowledge built during the ERC Proof of Concept and the Business Finland Research to Business projects at the University of Jyväskylä. At the time it was recognized that there is a lack of solutions for fully automated cfDNA extraction without high-speed moving components, such as a centrifuge. To support the use in a point-of-care (PoC) setting and to enable integration into PoC analyzers, a new fluidics-based approach enabling cfDNA extraction from a large sample volume (>10 ml) was needed. This led to the development of the novel technology implemented in our liquid biopsy sample preparation solution.
EIC Transition is a funding scheme targeted to support the maturation of a technology and the development of a business case around it. In FADEQ project the sample preparation technology is brought from a laboratory prototype to a market ready product. Our core team has comprehensive expertise in the scientific, technical and medical fields. It is supported by the board of directors and our advisory board, which has been composed of experts representing several of the large biotech companies.